IL-33/ST2 as a potential target for tumor immunotherapy

Area of Science:

• Immunology
• Cancer Biology
• Molecular Biology

Background:

• Interleukin-33 (IL-33) is an IL-1 family member initially found in cell nuclei.
• Released upon tissue damage, IL-33 binds ST2, acting as a Damage-Associated Molecular Pattern (DAMP).
• The IL-33/ST2 pathway is crucial for Th2 responses and immune regulation.

Purpose of the Study:

• To review the diverse roles of the IL-33/ST2 axis in the tumor microenvironment.
• To focus on IL-33-targeted immune cells and downstream signaling.
• To explore the potential of targeting the IL-33/ST2 axis in cancer immunotherapy.

Main Methods:

• Literature review of IL-33/ST2 signaling in cancer.
• Analysis of IL-33's effects on immune cells within the tumor microenvironment.
• Discussion of therapeutic strategies targeting the IL-33/ST2 pathway.

Main Results:

• IL-33/ST2 signaling promotes cancer development by expanding immunosuppressive cells (MDSCs, Tregs).
• Contradictory roles exist, as IL-33 can also enhance anti-tumor immunity via CD8+ T and NK cell infiltration.
• These dual effects complicate direct therapeutic targeting of the IL-33/ST2 axis.

Conclusions:

• The IL-33/ST2 axis exhibits versatile, context-dependent functions in the tumor microenvironment.
• Understanding these complex roles is essential for developing effective cancer immunotherapies.
• Targeting the IL-33/ST2 pathway holds promise for cancer treatment, but requires careful consideration of its dual effects.